Celltrion strives to boost stock price
Korean biotech firm Celltrion is striving to pump up its stock price through a series of stock buyback programs and other measures to improve shareholder value in an effort to dispel shareholder concerns over the company’s profitability and impacts from U.S. tariffs. Celltrion said Tuesday it has repurchased its own shares through six rounds of stock buyback programs so far this year, totaling 550 billion won ($402.75 million). The amount surpassed the 436 billion won of total buybacks it carried out last year. Celltrion Group Chairman Seo Jung-jin, the group's holding company Celltrion Holdings and its affiliate Celltrion Skincure recently announced plans to purchase Celltrion shares worth 50 billion won, 100 billion won and 50 billion won, respectively. Alongside Seo, other executives are also purchasing company shares to help boost the stock price. On Monday, Celltrion CEO Seo Jin-seok, the chairman’s eldest son, reported the purchase of 2,610 shares worth 400 million won. Kee Woo-sung and Kim Hyoung-ki, both vice chairmen, also reported buying 2,604 shares each. Since January, th
May 27, 2025By Nam Hyun-woo